RxDoctor Payments Data

Richard Toof, MD

Internal Medicine · Havertown, PANPI 1356389555

Payments from drug & device makers

$8,995in general payments, 2019–2025

Across 544 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$829
  • Astellas Pharma US Inc$632
  • Boehringer Ingelheim$511
  • plus $3K from 22 others

What the payments were for

  • Food & beverage$8,92099%
  • Education$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,995 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$230,160
Medicare patients
305
Services billed
2,686

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide77$122,151
JardianceEmpagliflozin63$94,376
OzempicSemaglutide50$77,743
Soliqua 100-33Insulin Glargine/Lixisenatide40$40,107
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$30,270
EliquisApixaban33$28,181
XareltoRivaroxaban20$20,568
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$20,452
TrulicityDulaglutide12$13,667
MyrbetriqMirabegron12$10,866
OxycontinOxycodone Hcl12$8,845
Tresiba Flextouch U-200Insulin Degludec11$6,605
GemtesaVibegron12$5,739
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$4,755
Atorvastatin Calcium445$4,633

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$829$135,81889 claims
Boehringer IngelheimJardiance$511$94,37663 claims
Novo NordiskOzempic$1,006$77,74350 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$391$40,10740 claims
GSKTrelegy Ellipta$1,149$30,27028 claims
PfizerEliquis, Paxlovid$169$29,61054 claims
Johnson & JohnsonXarelto$31$20,56820 claims
Astellas Pharma US IncMyrbetriq$632$10,86612 claims
AbbVieSynthroid$2,080$1,91826 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$27$1,701123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Havertown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →